secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001104659-24-008807
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron appoints Christopher Fenimore as CFO to succeed retiring Robert Landry
--------------------------------------------------------------------------------

- Christopher Fenimore promoted to SVP, Finance and CFO; effective day after 2023 10-K filing (expected Feb 5, 2024).
- Jason Pitofsky promoted to VP, Controller; no change in compensation.
- Fenimore's base salary increased to $660,000; granted equity award with target fair value of $5,000,000.
- Equity award includes options for 8,499 shares (4-year vest) and 2,370 RSUs (50% at years 2 and 4).
- Succession plan previously disclosed; Landry retiring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/tm244671d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-008807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer